Ondansetron hydrochloride dihydrate (ondansetron hydrochloride dihydrate; GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate) 中文名称: 盐酸昂丹司琼

别名: 盐酸昂丹司琼;盐酸蒽丹西酮;盐酸恩丹西酮;1,2,3,9-四氢-9-甲基-3-[(2-甲基咪唑-1-基)甲基]-4-氧代咔唑盐酸盐;昂丹司琼盐酸盐二水合物;Ondansetron Hydrochloride Dihydrate 昂丹司琼盐酸盐二水合物;昂丹司琼

目录号: V71163 纯度: ≥98%

COA 产品数据产品说明书 SDS

Ondansetron (GR 38032) HCl delicated 是一种口服生物利用度、选择性和竞争性 5-HT3 受体拮抗剂（BBB（血脑屏障）可渗透（可渗透））。

Ondansetron hydrochloride dihydrate (ondansetron hydrochloride dihydrate; GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate) CAS号: 103639-04-9
产品类别: 5-HT Receptor

产品仅用于科学研究，不针对患者销售

规格	价格	库存	数量
50mg
100mg
250mg
500mg
1g
5g
Other Sizes

加入购物车结帐大包装询价

020-31522723 sales@invivochem.cn

Other Forms of Ondansetron hydrochloride dihydrate (ondansetron hydrochloride dihydrate; GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate):

点击了解更多

InvivoChem产品被CNS等顶刊论文引用

Nature 2025, 643(8070):192-200.

Nature 2024 Dec 18.

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nat Neurosci 2024, 27:1468-1474.

Science Adv 2025, 11(33):eadr5199.

Nat Metab 2024, 6: 1108-1127.

Cell Stem Cell 2024, 31:106-126.e13.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

Immunity 2024,57:2651-2668.e12.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

产品描述
生物活性&实验参考方法
化学信息
溶解度数据
计算器
临床试验信息
相关产品

产品描述

Ondansetron (GR 38032) HCl delicated 是一种口服生物利用度、选择性和竞争性 5-HT3 受体拮抗剂（BBB（血脑屏障）可渗透（可渗透））。盐酸昂丹司琼脱水液用于预防癌症化疗、放射治疗和手术引起的恶心和呕吐。

生物活性&实验参考方法

靶点	5-HT3 Receptor
体内研究 (In Vivo)	在辐射诱发的异食癖模型中，脱水昂丹司琼盐酸盐（2 mg/kg；腹腔注射；单次）与地塞米松 (2 mg/kg) 和 CP-99,994 (15 mg/kg) 联合使用可预防放射病[1]。
动物实验	动物/疾病模型： ICR品系雄性小鼠（8周龄；30-36克；辐射诱导异食癖模型（高岭土摄入行为“异食癖”可能类似于小鼠的恶心和呕吐））[1]。剂量： 2 mg/kg 给药途径：腹腔注射；单次。实验结果：地塞米松使辐射诱导的高岭土摄入量略微降低至对照组的48%。与地塞米松（2 mg/kg）和CP-99,994（15 mg/kg）联合使用时，显示出良好的阻断辐射病活性。
药代性质 (ADME/PK)	代谢/代谢物肝脏半衰期：5.7 小时
毒性/毒理 (Toxicokinetics/TK)	妊娠期和哺乳期影响 ◉ 哺乳期用药概述昂丹司琼常用于剖宫产期间及术后缓解恶心，通常静脉注射剂量为 4 至 8 mg。剖宫产期间及术后使用昂丹司琼似乎不影响母乳喂养的开始。在产后接受昂丹司琼治疗的女性中，以及在药代动力学研究中，均未报告婴儿出现不良反应。昂丹司琼在产后哺乳期妇女中的应用研究尚不充分，但该药已获准用于 1 个月大的婴儿。计算机模型显示，母乳中的药物浓度远低于此剂量。无需特别预防措施。 ◉ 对母乳喂养婴儿的影响一项对78名产后接受静脉注射昂丹司琼的妇女进行的药代动力学研究表明，其母乳喂养的婴儿未出现不良反应。 ◉ 对泌乳和母乳的影响一项随机、双盲研究比较了安慰剂与剖宫产术后静脉注射4 mg昂丹司琼预防术后恶心呕吐的效果。两组首次母乳喂养的时间无差异。一项回顾性研究比较了三种剖宫产妇女的用药方案：麻醉前和分娩期间使用右美托咪定（n = 115）、麻醉前和分娩期间使用生理盐水，分娩后使用右美托咪定（n = 109）以及麻醉前和分娩期间使用生理盐水（n = 168）。所有女性均根据需要服用4毫克昂丹司琼，并在拆线前服用。各组女性平均昂丹司琼总摄入量为6毫克至9毫克。各组首次泌乳时间相似（25至28分钟）。
参考文献	[1]. Ondansetron, dexamethasone and an NK1 antagonist block radiation sickness in mice. Pharmacol Biochem Behav. 2005 Sep;82(1):24-9. [2]. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs. 1996 Nov;52(5):773-94.
其他信息	盐酸昂丹司琼属于咔唑类药物。盐酸昂丹司琼是昂丹司琼外消旋体的盐酸盐，昂丹司琼是一种咔唑衍生物，也是一种选择性竞争性5-羟色胺3型（5-HT3）受体拮抗剂，具有止吐活性。尽管其作用机制尚未完全阐明，但昂丹司琼似乎能够竞争性阻断5-羟色胺在胃肠道外周以及中枢神经系统延髓后区（呕吐化学感受器触发区（CTZ）所在区域）的5-HT3受体上的作用，从而抑制化疗和放疗引起的恶心和呕吐。一种竞争性5-羟色胺3型受体拮抗剂。它能有效治疗由细胞毒性化疗药物（包括顺铂）引起的恶心和呕吐，并有报道称其具有抗焦虑和抗精神病作用。另见：盐酸昂丹司琼（注释已移至）。

*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性

化学信息 & 存储运输条件

分子式	C18H24CLN3O3
分子量	365.85
精确质量	365.15
CAS号	103639-04-9
相关CAS号	Ondansetron;99614-02-5;Ondansetron hydrochloride;99614-01-4
PubChem CID	59774
外观&性状	White to off-white solid powder
密度	1.1±0.1 g/cm3
沸点	267.0±9.0 °C at 760 mmHg
熔点	231-232ºC
闪点	144.9±5.1 °C
蒸汽压	0.0±0.5 mmHg at 25°C
折射率	1.523
LogP	-0.37
tPSA	58.28
氢键供体(HBD)数目	3
氢键受体(HBA)数目	4
可旋转键数目(RBC)	2
重原子数目	25
分子复杂度/Complexity	440
定义原子立体中心数目	0
SMILES	CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C.O.O.Cl
InChi Key	VRSLTNZJOUZKLX-UHFFFAOYSA-N
InChi Code	InChI=1S/C18H19N3O.ClH.2H2O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;;;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H;2*1H2
化学名	9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;dihydrate;hydrochloride
HS Tariff Code	2934.99.9001
存储方式	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意： (1). 请将本产品存放在密封且受保护的环境中（例如氮气保护），避免吸湿/受潮和光照。 (2). 该产品在溶液状态不稳定，请现配现用。
运输条件	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

溶解度数据

溶解度 (体外实验)	DMSO: 100 mg/mL (273.34 mM) H2O: 16.67 mg/mL (45.57 mM)
溶解度 (体内实验)	配方 1 中的溶解度: ≥ 2.5 mg/mL (6.83 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。配方 2 中的溶解度:* ≥ 2.5 mg/mL (6.83 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。 *20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、以上所有助溶剂都可在 Invivochem.cn网站购买。

溶解度 (体外实验)

DMSO: 100 mg/mL (273.34 mM)
H2O: 16.67 mg/mL (45.57 mM)

溶解度 (体内实验)

配方 1 中的溶解度: ≥ 2.5 mg/mL (6.83 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

配方 2 中的溶解度: ≥ 2.5 mg/mL (6.83 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、以上所有助溶剂都可在 Invivochem.cn网站购买。

制备储备液		1 mg	5 mg	10 mg
	1 mM	2.7334 mL	13.6668 mL	27.3336 mL
	5 mM	0.5467 mL	2.7334 mL	5.4667 mL
	10 mM	0.2733 mL	1.3667 mL	2.7334 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器

质量

浓度

体积

分子量*

计算重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

计算制备已知体积和浓度的溶液所需的化合物的质量
计算将已知质量的化合物溶解到所需浓度所需的溶液体积
计算特定体积中已知质量的化合物产生的溶液的浓度

参见示例

使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？

在分子量（MW）框中输入350.26
在“浓度”框中输入10，然后选择正确的单位（mM）
在“体积”框中输入5，然后选择正确的单位（mL）
单击“计算”按钮
答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。

浓度 (起始)

体积 (起始)

浓度 (终)

体积 (终)

计算重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：

在C1框中输入10，然后选择正确的单位（mM）
在C2框中输入25，然后选择正确的单位（μM）
在V2框中输入25，然后选择正确的单位（mL）
单击“计算”按钮
答案62.5μL（0.1 ml）出现在V1框中

分子式

分子量

g/mol

计算重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4 c12h18n3o4
计算化合物摩尔质量（分子量）的说明：

要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。

分子质量、分子量、摩尔质量和摩尔量的定义：

分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。

配液体积

质量

配液浓度

计算重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

输入试剂的质量、所需的配液浓度以及正确的单位
单击“计算”按钮
答案显示在体积框中

动物体内实验配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg

动物平均体重 g

每只动物给药体积 μL

动物数量

第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。

% DMSO

% Tween 80

% ddH₂O

计算重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意： (1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息

Title:Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
Status:Completed
updateDate:2025-12-05
Ctid:NCT02473042

Link: https://clinicaltrials.gov/ct2/show/NCT02473042

Conditions:Post-Operative Nausea and Vomiting|Breast Cancer
Interventions:Pepcid
Phase:N/A

Title:Multimodal Analgesia Effect on Post Surgical Patient
Status:Active, not recruiting
updateDate:2025-08-08
Ctid:NCT04240626

Link: https://clinicaltrials.gov/ct2/show/NCT04240626

Conditions:Obesity, Morbid|Surgery|Bariatric Surgery Candidate
Interventions:Tylenol Suspension
Phase:Phase 4

Title:PROUD Study - Preventing Opioid Use Disorders
Status:Terminated
updateDate:2023-06-22
Ctid:NCT04766996

Link: https://clinicaltrials.gov/ct2/show/NCT04766996

Conditions:Anesthesia|Opioid Use
Interventions:Toradol
Phase:Phase 4

View More

Title:Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
Status:Completed
updateDate:2022-04-04
Ctid:NCT03973047

Link: https://clinicaltrials.gov/ct2/show/NCT03973047

Conditions:Nausea
Interventions:Placebo
Phase:Phase 1

Title:Pain Management After Shoulder Arthroplasty
Status:Unknown status
updateDate:2021-05-04
Ctid:NCT04872270

Link: https://clinicaltrials.gov/ct2/show/NCT04872270

Conditions:Caffeine|Pain, Joint
Interventions:Zofran 4Mg Tablet
Phase:Phase 3

Title:Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets
Status:Completed
updateDate:2020-07-29
Ctid:NCT01217190

Link: https://clinicaltrials.gov/ct2/show/NCT01217190

Conditions:Nausea and Vomiting, Postoperative|Nausea With Vomiting Chemotherapy-Induced
Interventions:Zofran (ODT)
Phase:Phase 1/Phase 2

Title:BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis
Status:Completed
updateDate:2019-02-20
Ctid:NCT02246439

Link: https://clinicaltrials.gov/ct2/show/NCT02246439

Conditions:Gastroenteritis|Gastritis
Interventions:Placebo Oral Tablet
Phase:Phase 3

Title:Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain
Status:Completed
updateDate:2018-10-29
Ctid:NCT03254459

Link: https://clinicaltrials.gov/ct2/show/NCT03254459

Conditions:Pain, Postoperative
Interventions:Zofran
Phase:Phase 2

Title:Decreasing Narcotics in Advanced Pelvic Surgery
Status:Completed
updateDate:2016-08-17
Ctid:NCT02110719

Link: https://clinicaltrials.gov/ct2/show/NCT02110719

Conditions:Narcotic Use|Pain|Constipation|Nausea
Interventions:zofran
Phase:Phase 4

Title:The Effect of Dexamethasone in Combination With Paracetamol and Ibuprofen on Postoperative Pain After Spine Surgery
Status:Completed
updateDate:2015-10-27
Ctid:NCT01953978

Link: https://clinicaltrials.gov/ct2/show/NCT01953978

Conditions:Pain
Interventions:Ibuprofen
Phase:Phase 4

Title:The Effect of Chlorzoxazone on Moderate to Severe Postoperative Pain After Spine Surgery
Status:Completed
updateDate:2015-09-17
Ctid:NCT01933542

Link: https://clinicaltrials.gov/ct2/show/NCT01933542

Conditions:Chlorzoxazone|Postoperative Pain
Interventions:Zofran
Phase:Phase 4

Title:Droperidol and Cardiac Repolarization
Status:Completed
updateDate:2013-08-07
Ctid:NCT01819857

Link: https://clinicaltrials.gov/ct2/show/NCT01819857

Conditions:Cardiac Repolarization
Interventions:Zofran 8 mg
Phase:Phase 4

Title:Improving Tolerance of Treatment of Pulmonary MAC Infections
Status:Withdrawn
updateDate:2013-04-04
Ctid:NCT01719042

Link: https://clinicaltrials.gov/ct2/show/NCT01719042

Conditions:Mycobacterium Avium Complex|Adverse Effects
Interventions:Ensure
Phase:Phase 2

Title:Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions
Status:Completed
updateDate:2008-04-16
Ctid:NCT00659074

Link: https://clinicaltrials.gov/ct2/show/NCT00659074

Conditions:Healthy
Interventions:Zofran
Phase:Phase 1

Title:Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions
Status:Completed
updateDate:2008-04-11
Ctid:NCT00654277

Link: https://clinicaltrials.gov/ct2/show/NCT00654277

Conditions:Healthy
Interventions:Zofran
Phase:Phase 1

Title:Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions
Status:Completed
updateDate:2008-04-11
Ctid:NCT00653458

Link: https://clinicaltrials.gov/ct2/show/NCT00653458

Conditions:Healthy
Interventions:Zofran
Phase:Phase 1

Title:A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 36 mg) Dose of the Neurokinin-1 Receptor Antagonist, Vestipitant (GW597599), Compared with a Single 4 mg Intravenous Ondansetron Hydrochloride Dose for the Treatment of Breakthrough Post-Operative Nausea and Vomiting after Failed Prophylaxis with an Ondansetron-Containing Regimen in Patients Undergoing Non-Emergency Surgical Procedures
Status:Prematurely Ended
Date:2012-04-05
Eudractnumber:2011-005216-28

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005216-28

Condition:Post-operative nausea and vomiting (PONV)
Phase:Phase 2

Title:A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.
Status:Completed, Ongoing
Date:2011-08-04
Eudractnumber:2010-022872-30

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022872-30

Condition:Study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC
Phase:Phase 3

Title:A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
Status:Completed
Date:2011-05-23
Eudractnumber:2010-022971-79

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022971-79

Condition:Postoperative nausea and vomiting (PONV)
Phase:Phase 3

Title: A comparative double-blind placebo-controlled study between alizapride and ondansetron for the prevention of postoperative nausea and vomiting.
Status:Completed
Date:2008-09-05
Eudractnumber:2008-004789-20

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004789-20

Condition:Prevention of post-operative nausea and vomiting.
Phase:Phase 4

Title:Ondansetronin vaikutus parasetamolin kipulääkevasteeseen tähystyksen kautta tehtävän kohdunpoiston yhteydessä
Status:Completed
Date:2007-11-09
Eudractnumber:2007-005311-25

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005311-25

Condition:Tähystysleikkauksen jälkeinen kipu
Phase:Phase 4

Title:Brush-evoked allodynia in patients with peripheral neuropathy before and following intravenous infusion of ondansetron. A randomised, double-blind, placebo controlled, cross-over study.
Status:Completed
Date:2007-01-03
Eudractnumber:2006-000526-31

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000526-31

Condition:Peripheral neuropathy
Phase:Phase 4

Title:A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy (Study #2)
Status:Completed
Date:2006-11-23
Eudractnumber:2006-003512-22

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003512-22

Condition:Chemotherapy-induced Nausea and Vomitting
Phase:Phase 3

Title:A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, administered in Combination with ZOFRAN and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-Based Chemotherapy
Status:Completed
Date:2006-09-11
Eudractnumber:2006-002033-21

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002033-21

Condition:Chemotherapy induced nausea and vomiting (CINV) due to Highly Emetogenic Chemotherapy (HEC)
Phase:Phase 3

Title:A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced By Moderately Emetogenic Chemotherapy
Status:Completed
Date:2006-07-24
Eudractnumber:2006-000781-37

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000781-37

Condition:Chemotherapy induced nausea and vomiting (CINV) due to Moderately Emetogenic Chemotherapy (MEC)
Phase:Phase 3

Title:A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study
Status:Prematurely Ended
Date:2006-06-12
Eudractnumber:2006-001761-42

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001761-42

Condition:Postoperative Nausea and Vomiting
Phase:Phase 3

Title:A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status:Completed
Date:2006-03-29
Eudractnumber:2005-005856-42

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005856-42

Condition:Postoperative Nausea and Vomiting (PONV)
Phase:Phase 3

Title:A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status:Completed
Date:2006-03-20
Eudractnumber:2005-005855-16

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005855-16

Condition:Postoperative Nausea and Vomiting (PONV)
Phase:Phase 3

Title:A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects
Status:Completed
Date:2005-05-20
Eudractnumber:2004-000370-31

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000370-31

Condition:Post Operative Nausea and Vomiting (PONV)Post Discharge Nausea and Vomiting (PDNV)
Phase:Phase 2

Title:A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 mg and 18 mg) Formulations of the Neurokinin-1 Receptor Antagonist, GW597599, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for PONV
Status:Completed
Date:2005-02-08
Eudractnumber:2004-001021-22

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001021-22

Condition:Post Operative Nausea and Vomiting (PONV)Post Discharge Nausea and Vomiting (PDNV)
Phase:Phase 2

Title:A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjunction with a single intravenous dose of ondansetron for the prevention of post-operative and post-discharge nausea and vomiting in at risk females undergoing laparoscopic/laparotomic surgical procedures.
Status:Completed
Date:2005-02-01
Eudractnumber:2004-000369-37

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000369-37

Condition:Post Operative Nausea and Vomiting (PONV)Post Discharge Nausea and Vomiting (PDNV)
Phase:Phase 2

Title:
Status:Completed
Date:2005-01-25
Eudractnumber:2004-001020-20

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001020-20

Condition:Chemotherapy Induced Nausea and Vomiting (CINV) 0 Moderately Emetogenic Chemotherapy (MEC)
Phase:Phase 2

Title:A Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 When Administered at daily doses of 50 mg, 100 mg, and 150 mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy.
Status:Completed
Date:2005-01-25
Eudractnumber:2004-000371-34

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000371-34

Condition:Chemotherapy-Induced Nausea and Vomiting (CINV) - Highly Emetogenic Chemotherapy (HEC)
Phase:Phase 2

Title:Efficacité de l'ondansetron sur les vomissements dus aux gastroentérites aiguës pédiatriques en période hivernale
Status:Ongoing
Date:
Eudractnumber:2011-004372-11

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004372-11

Condition:Enfants de 6 mois à 15 ans inclus, consultant aux urgences pour gastroentérite aiguë et ayant eu au moins 3 vomissements non bilieux, non sanglants dans les 12 heures qui précèdent la consultation.
Phase:Phase 3